Igenica Header
  | | | | |

 

Igenica Management
Mike Rothe, Ph.D.
Chief Executive Officer
Guoqing Chen, Ph.D. Vice President of Research
Igenica Management
David V. Goeddel, Ph.D.
Chairman
John D. Diekman, Ph.D.
Carl L. Gordon, Ph.D., CFA
Robert Schreiber, Ph.D.
Mike Rothe, Ph.D.
Igenica Management
Robert Schreiber, Ph.D.
Chairman
Frederick Appelbaum, M.D.  
Thomas Kipps, M.D., Ph.D.  
Richard Klausner, M.D.  
Jeffrey V. Ravetch, M.D., Ph.D.  
Richard Ulevitch, Ph.D.  
Emil Unanue, M.D.  
 
 
 
 
Igenica Leadership

Igenica has assembled a management team with deep operational experience and strong antibody drug discovery expertise.  Supported by a Scientific Advisory Board that comprises key thought leaders in the fields of oncology and immunology and advised by an experienced Board of Directors with a track record of success in the industry, Igenica is well positioned to realize its mission of discovering and developing breakthrough therapeutics for the treatment of cancer.